- Home
- AMGN vs TSLA Comparison
AMGN vs TSLA Comparison
Compare AMGN & TSLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMGN | TSLA |
|---|---|---|
| Founded | 1980 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.7B | 1.6T |
| IPO Year | 2002 | 2010 |
Fundamental Metrics
Financial Performance| Metric | AMGN | TSLA |
|---|---|---|
| Price | $345.89 | $408.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 19 | 32 |
| Target Price | $351.05 | ★ $405.47 |
| AVG Volume (30 Days) | 2.1M | ★ 42.6M |
| Earning Date | 04-30-2026 | 04-22-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 88.23 | N/A |
| EPS | ★ 3.34 | 0.13 |
| Revenue | $25,424,000,000.00 | ★ $94,827,000,000.00 |
| Revenue This Year | $5.00 | $10.82 |
| Revenue Next Year | $2.45 | $16.06 |
| P/E Ratio | ★ $104.66 | $3,007.69 |
| Revenue Growth | ★ 8.83 | N/A |
| 52 Week Low | $269.77 | $288.77 |
| 52 Week High | $391.29 | $498.83 |
Technical Indicators
Market Signals| Indicator | AMGN | TSLA |
|---|---|---|
| Relative Strength Index (RSI) | 56.02 | 48.26 |
| Support Level | $334.95 | $386.85 |
| Resistance Level | $356.53 | $414.07 |
| Average True Range (ATR) | 7.43 | 13.69 |
| MACD | 2.09 | -4.40 |
| Stochastic Oscillator | 66.41 | 36.72 |
Price Performance
Historical ComparisonAbout AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About TSLA Tesla Inc.
Tesla is a vertically integrated battery electric vehicle automaker and developer of real world artificial intelligence software, which includes autonomous driving and humanoid robots. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to begin selling a sports car and offer a robotaxi service. Global deliveries in 2025 were nearly 1.64 million vehicles. The company sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network and an auto insurance business.